Delivering a Diversified Long-term Revenue Stream

Fortress Biotech, Inc. is an innovative biopharmaceutical company focused on delivering a diversified, long-term revenue stream to our shareholders through the creation of a diverse portfolio of marketed products, as well as in-licensing opportunities and through the development of high-potential preclinical and clinical-stage product candidates. Fortress currently has nine marketed products and over 25 programs in development.

Recent Event

65th American Society of Hematology (“ASH”) Annual Meeting

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates. The company has eight marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, St. Jude Children’s Research Hospital, Nationwide Children’s Hospital and Sentynl.

Fortress Biotech at a Glance


Programs in Development


Marketed Products

Fortress Biotech Performance

Year over year company performance

As of Dec. 31, 2021 • 10-K 2021

Investor Relations Contacts


Fortress Biotech, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154

Investor Relations

Jaclyn Jaffe
Nicole McCloskey
T: 781-652-4500

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436